Recruit Rockstars Podcast #367: How His VC-Backed Team Made Drug Development Faster

When creating new drugs, it’s often difficult to find enough patients for clinical trials.

And that limits the number of trials you can run.

Which slows down drug development. And costs lives.

Charles Fisher is out to change all that.

He’s CEO of Unlearn.AI

Based in San Francisco, Unlearn helps biopharma companies develop drugs more efficiently by leveraging AI to reduce the number of patients required for placebo controls in clinical trials.

In fact, Unlearn.AI enables clinical trials that are twice as fast, require fewer patients, produce better evidence about efficacy, and in which fewer patients need to be given placebos.

Last week, the company announced a major venture investment from Epic Ventures, Alumni Ventures Group, and the global Pharma company Eisai

Charles & his team are creating the first commercial product providing AI-derived Intelligent Control Arms to increase the statistical power of clinical trials, and accelerate study timelines in Alzheimer’s Disease.

In this 20-minute conversation, he reveals how he’s scaling the team.

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.
White Papers

Applications of Digital Twins in Clinical Trials for Alzheimer’s Disease

Press

Unlearn.AI named to the 2021 CB Insights AI 100 List of Most Innovative Artificial Intelligence Startups

Blog

Welcoming Dr. Taylor to Unlearn.AI’s Board of Directors

I’m honored to have such an inspirational and experienced leader like Dr. Taylor join our board.
The AI 100 is CB Insights' annual list of the 100 most promising private AI companies in the world.
How Digital Twins make it possible to design and run more efficient clinical trials with well-defined statistical properties.